Yasir Furkan Cagin, Muhammet Cengiz, Yuksel Seckin, Ayse Nuransoy Cengiz

Investigation of hepatitis B virus prevalence and reactivation frequency in malignancy patients administering chemotherapy

Aim: This study aimed to investigate the frequency at which physicians test hepatitis B virus (HBV) serology before treatment and the rate of hepatitis B virus reactivation (HBVr) after treatment in patients undergoing chemotherapy (CT) due to a solid organ malignancy (SOM) or hematological malignancy (HM). Materials and Methods: Baseline clinical feature, HBV serology, and liver function test data for 1275 patients ≥ 18 years of age who underwent CT for the first time due to various SOMs and HMs from 2015-2017 were obtained from the database and retrospectively analyzed. HBV serology was studied in 296 (201 HM, 95 SOM) of the 1275 patients retrieved from the database. Results: The prevalence of HBV was 9.5% (121 patients). Only 49 (40.4%) HBV-positive patients had HBV DNA. Of those, 72 (59.5%) underwent prophylactic antiviral therapy. HBVr was detected in only 3 patients (1.5%), and all of those patients had HMs and were recommended oral antiviral therapy but did not. Conclusion: In patients with SOMs, the screening rates of HBV serology, as well as prophylaxis and follow-up HMs were extremely low. Therefore, these patients should be screened for HBV serology and prophylactic treatment should be given when necessary for HBVr.

PDF

___

1. Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis 2016;20:607-28.
2. Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546-55.
3. Maynard J. Hepatitis B: global importance and need for control. Vaccine 1990;8:18-20.
4. Ott J, Stevens G, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of agespecific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-9.
5. Gupta S, Govindarajan S, Fong T-L, et al. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol Hepatol 1990;12:562-8.
6. Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553-61.
7. 7. Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148:215-9.
8. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Gastroenterol 2008;148:519-28.
9. Mozessohn L, Chan K, Feld J, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a metaanalysis. J Viral Hepat 2015;22:842-9.
10. Kim SJ, Hsu C, Song Y-Q, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013;49:3486-96.
11. Li H, Zhang H-m, Chen L-f, et al. Prophylactic lamivudine to improve the outcome of HBsAgpositive lymphoma patients during chemotherapy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2015;39:80-92.
12. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatol 2008;47:844-53.
13. Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatol 2015;61:703-11.
14. Sarin S, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.
15. Liver EAFTSOT. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
16. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatol 2009;50:661-2.
17. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
18. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000;61:362-6.
19. Tran T, Rakoski M, Martin P, et al. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther 2010;31:240-6.
20. Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010;28:3199-202.
21. Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. Jama 2015;313:1617-8.
22. Wi C-I, Loo NM, Larson JJ, Moynihan TJ, et al. Low level of hepatitis B virus screening among patients receiving chemotherapy. Clin Gastroenterol Hepatol 2015;13:970-5.
23. Hwang JP, Fisch MJ, Zhang H, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract 2012;8:e32-e9.
24. Laiwatthanapaisan R, Sripongpun P, Chamroonkul N, et al. Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand. Clin Mol Hepatol 2019;25:366.
25. Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatol 2014;59:2092-100.